Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865947 | 0.86 | ALDH1A1 (0.30) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL13071312 | 0.86 | ADAM17 (0.30) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL28473630 | 0.85 | — | — | |
| SCHEMBL17735697 | 0.85 | ALDH1A1 (0.30) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL13990674 | 0.84 | BACE1 (0.30) | — | |
| SCHEMBL14144493 | 0.84 | — | — | |
| SCHEMBL18344257 | 0.84 | — | — | |
| SCHEMBL22650155 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL22635959 | 0.83 | — | — | |
| SCHEMBL4620757 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2020018941-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20170029514-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2017-02-02 | — | — | US | disclosed |
| EP-2612682-A2 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates | ImmunoGen, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2596804-A2 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates | ImmunoGen, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2596803-A2 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates | ImmunoGen, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-1689846-B1 | Conjugates of maytansinoid DM1 with antibody trastuzumab, linked through a non-cleavable linker, and its use in the treatment of tumours | IMMUNOGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8198417-B2 | Potent, durable cytotoxic agents; tissue targeted therapy; tumors, autoimmune diseases, graft versus host disease, viral and parasite infections | IMMUNOGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | ALDH1A1 2452/4885CYP1A2 4668/4885HPGD 3990/4885 |
| US-20170029514-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | ALDH1A1 1167/4885CYP1A2 3278/4885HPGD 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.